CorMedix (CRMD)
(Delayed Data from NSDQ)
$7.30 USD
-0.08 (-1.08%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $7.30 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
CorMedix (CRMD) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$12.50 | $19.00 | $9.00 | 69.38% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for CorMedix comes to $12.50. The forecasts range from a low of $9.00 to a high of $19.00. The average price target represents an increase of 69.38% from the last closing price of $7.38.
Analyst Price Targets (4 )
Broker Rating
CorMedix currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, two are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 50% and 50% of all recommendations. A month ago, Strong Buy made up 50%, while Buy represented 50%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/15/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
8/15/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
6/20/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
1/30/2024 | JMP Securities | Jason N Butler | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 4 |
Average Target Price | $12.50 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 79 of 253 |
Current Quarter EPS Est: | -0.10 |
CRMD FAQs
CorMedix Inc (CRMD) currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 4 brokerage firms.
The average price target for CorMedix Inc (CRMD) is $12.50. The current on short-term price targets is based on 1 reports.
The forecasts for CorMedix Inc (CRMD) range from a low of $9 to a high of $19. The average price target represents a increase of $69.38 from the last closing price of $7.38.
The current UPSIDE for CorMedix Inc (CRMD) is 69.38%
Based on short-term price targets offered by four analysts, the average price target for CorMedix comes to $12.50. The forecasts range from a low of $9.00 to a high of $19.00. The average price target represents an increase of 69.38% from the last closing price of $7.38.